

## Supplementary Information

### **Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia**

Oliver Parting<sup>1</sup>, Samantha Langer<sup>2</sup>, Maja Kim Kuepper<sup>1</sup>, Caroline Wessling<sup>3</sup>, Shaoguang Li<sup>4</sup>, Till Braunschweig<sup>5</sup>, Nicolas Chatain<sup>1</sup>, Michael Huber<sup>6</sup>, Tim H Brümmendorf<sup>1</sup>, Steffen Koschmieder<sup>1</sup>, and Mirle Schemionek<sup>1</sup>

<sup>1</sup>Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, University Hospital RWTH Aachen, Aachen, Germany; <sup>2</sup>Department of Transfusion Medicine, University Hospital Essen, Essen, Germany; <sup>3</sup>Department of Neurosurgery, Clemens Hospital, Muenster, Germany; <sup>4</sup>Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA; <sup>5</sup>Department of Pathology, University Hospital RWTH Aachen, Aachen, Germany; <sup>6</sup>Institute of Biochemistry and Molecular Immunology, RWTH Aachen University, Aachen, Germany

**Supplementary Table S1: sequences of primer and probes applied in this study**

<b>Oligonucleotide</b>	<b>Sequence 5'-3'</b>
Bcr-Abl forward	CGTCAACTCAGCCACTGG
Bcr-Abl reverse	GGCTTCACTCAGACCCTGA
Bcr-Abl probe	FAM-AGCGGCCAGTATCATCTGACTTTGAGC-TAMRA
GAPDH forward	TTGTGCAGTGCCAGCCTC
GAPDH reverse	CCAATACGGCCAATCCG
GAPDH probe	FAM-TCCCGTAGACAAAATGGTGAAGGTCGGT-TAMRA
p16 forward	TCATCATCACCTGAATCGGGG
p16 reverse	AAAGCGAACTCGAGGAGAGC
p19 forward	GCCGCACCGGAATCCT
p19 reverse	TTGAGCAGAAGAGCTGCTACGT
p21 forward	GTGGGTCTGACTCCAGCCC
p21 reverse	CCTTCTCGTGAGACGCTTAC
p27 forward	TCGCAAAACAAAAGGGCCAA
p27 reverse	CTTAATTCGGAGCTGTTTACGTC

**Supplementary Table S2: shRNAs sequences**

<b>shRNA</b>	<b>Sequence 5'-3'</b>
#1_shRNA_ FcyRIIb_F	TCGAGTGCTGTTGACAGTGAGCGCCGGTGACACTGAC ATGCGAAGTAGTGAAGCCACAGATGTACTTCGCATGT CAGTGTACCGTTGCCTACTGCCTCGGAG
#1_shRNA_ FcyRIIb_R	AATTCTCCGAGGCAGTAGGCAACGGTGACACTGACAT GCGAAGTACATCTGTGGCTTCACTACTTCGCATGTCA GTGTACCGGCGCTCACTGTCAACAGCAC
#2_shRNA_ FcyRIIb_F	TCGAGTGCTGTTGACAGTGAGCGCGGGATGCTGTAGA TATTAAGTAGTGAAGCCACAGATGTACTTTAATATCTA CAGCATCCCTGCCTACTGCCTCGGAG
#2_shRNA_ FcyRIIb_R	AATTCTCCGAGGCAGTAGGCAAGGGATGCTGTAGATA TTAAAGTACATCTGTGGCTTCACTACTTTAATATCTACA GCATCCCGCGCTCACTGTCAACAGCAC
#3_shRNA_ FcyRIIb_F	TCGAGTGCTGTTGACAGTGAGCGGAGGATGCTGTAGAT ATTAAAGATAGTGAAGCCACAGATGTATCTTTAATATCT ACAGCATCCCTGCCTACTGCCTCGGAG
#3_shRNA_ FcyRIIb_R	AATTCTCCGAGGCAGTAGGCAAGGGATGCTGTAGATAT TAAAGATACATCTGTGGCTTCACTATCTTTAATATCTAC AGCATCCTCGCTCACTGTCAACAGCAC
Scrambled_ FcyRIIb_F	TCGAGTGCTGTTGACAGTGAGCGCGGTAAATTATTGT GATTTAGTTAGTGAAGCCACAGATGTAACATAATCACA ATAATTTACCTTGCCTACTGCCTCGGAG
Scrambled_ FcyRIIb_R	AATTCTCCGAGGCAGTAGGCAAGGTAATTATTGTGAT TTAGTTACATCTGTGGCTTCACTAACTAAATCACAATAA TTTACCGCGCTCACTGTCAACAGCAC

**Supplementary Table S3: Antibodies for immunophenotyping applied in this study**

<b>Antibody</b>	<b>Supplier</b>	<b>Cell clone</b>
CD3-PE Cy5	Biolegend	17A2
Gr-1-PE Cy5	Biolegend	RB6-8C5
Gr-1-Tri Color	Life technologies	RM3006
CD4-Tri Color	Life technologies	MCD0406
CD4-PE Cy5	Biolegend	RM4-5
CD8 $\alpha$ -Tri Color	Life technologies	MCD0806
CD8a-PECy5	Biolegend	53-6.7
CD11b-PE Cy5	Biolegend	M1/70
CD117(cKit) -APC Cy7	Biolegend	2B8
Sca-1-Biotin	Biolegend	E12-161.7
Streptavidin-PE Cy7	BD Bioscience	
CD45.1-APC	Biolegende	A20
CD45.2-Pacific Blue	Biolegende	104
CD32b-PE	eBioscience	AT130-2
CD32b-APC	eBioscience	AT130-2
Rat IgG2a kappa-PE	eBioscience	eBR2a
Rat IgG2a kappa-APC	eBioscience	eBR2a